Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758548 | 0.86 | KMT2A (0.57) | MEN1KMT2AALDH1A1TP53LMNA | |
| SCHEMBL17580571 | 0.81 | P2RX3 (0.41) | HTTLPAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL2203559 | 0.80 | ALDH1A1 (0.56) | HTTALDH1A1LMNAMAPTGAA | |
| SCHEMBL12157435 | 0.80 | HTT (0.51) | HTTLPAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL6123236 | 0.79 | HTT (0.50) | HTTALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL12946520 | 0.79 | HTT (0.50) | HTTLPAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL28617698 | 0.78 | HTT (0.47) | HTTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL15508018 | 0.78 | KMT2A (0.39) | HTTMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL9281838 | 0.77 | APP (0.51) | TRPV4LPAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL7530972 | 0.76 | KDM4E (0.53) | MEN1KMT2AALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-11897877-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-19 | — | — | US | disclosed |
| EP-3293183-B1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-10280150-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180141944-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-05-24 | — | — | US | disclosed |
| US-9834552-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| EP-2892889-B1 | INHIBITOR COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-9409907-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160222009-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220570-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20150239884-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | BUB1B, BUB1, CDK1 | HTT 2631/4885TRPV4 3953/4885LPAR1 1170/4885 |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | HTT 2840/4885TRPV4 3815/4885LPAR1 1114/4885 |
| US-20150239884-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | HTT 2840/4885TRPV4 3815/4885LPAR1 1114/4885 |
| US-10280150-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | HTT 622/4885TRPV4 4877/4885LPAR1 4581/4885 |
| US-11046688-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | HTT 2840/4885TRPV4 3815/4885LPAR1 1114/4885 |
| US-20180141944-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | HTT 2840/4885TRPV4 3815/4885LPAR1 1114/4885 |
| US-20160222009-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | HTT 2840/4885TRPV4 3815/4885LPAR1 1114/4885 |
| US-11897877-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | HTT 2840/4885TRPV4 3815/4885LPAR1 1114/4885 |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | HTT 2840/4885TRPV4 3815/4885LPAR1 1114/4885 |
| US-20160220570-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | HTT 2840/4885TRPV4 3815/4885LPAR1 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.